Search Results - "van’t Veer, Mars B."

Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial by Doorduijn, Jeanette K., Zijlstra, Josee M., Lugtenburg, Pieternella J., Kersten, Marie Josee, Böhmer, Lara H., Minnema, Monique C., MacKenzie, Marius A., van Marwijk Kooij, Rien, Jongh, Eva, Snijders, Tjeerd J.F., Weerdt, Okke, Gelder, Michel, Hoogendoorn, Mels, Leys, Rineke B.L., Kibbelaar, Robby E., Jong, Daphne, Chitu, Dana A., Van’t Veer, Mars B., Kluin‐Nelemans, Hanneke C.

“…Rituximab‐containing induction followed by autologous stem cell transplantation (ASCT) is the standard first‐line treatment for young mantle cell lymphoma…”
Get full text

Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease by ALEMAN, Berthe M. P, VAN DEN BELT-DUSEBOUT, Alexandra W, KLOKMAN, Willem J, VAN'T VEER, Mars B, BARTELINK, Harry, VAN LEEUWEN, Flora E

“…To assess long-term cause-specific mortality of young Hodgkin's disease (HD) patients. The study population consisted of 1,261 patients treated for HD before…”
Get full text

Second Malignant Neoplasms Among Long-Term Survivors of Hodgkin’s Disease: A Population-Based Evaluation Over 25 Years by DORES, Graca M, METAYER, Catherine, ANDERSSON, Michael, WIKLUND, Tom, JOENSUU, Timo, VAN'T VEER, Mars B, STOVALL, Marilyn, GOSPODAROWICZ, Mary, TRAVIS, Lois B, CURTIS, Rochelle E, LYNCH, Charles F, CLARKE, E. Aileen, GLIMELIUS, Bengt, STORM, Hans, PUKKALA, Eero, VAN LEEUWEN, Flora E, HOLOWATY, Eric J

“…To quantify the relative and absolute excess risks (AER) of site-specific second cancers, in particular solid tumors, among long-term survivors of Hodgkin's…”
Get full text

Breast Cancer Risk in Female Survivors of Hodgkin's Lymphoma: Lower Risk After Smaller Radiation Volumes by DE BRUIN, Marie L, SPARIDANS, Judith, ALEMAN, Berthe M. P, VAN LEEUWEN, Flora E, VAN'T VEER, Mars B, NOORDIJK, Evert M, LOUWMAN, Marieke W. J, ZIJLSTRA, Josée M, VAN DEN BERG, Hendrik, RUSSELL, Nicola S, BROEKS, Annegien, BAAIJENS, Margreet H. A

“…We assessed the long-term risk of breast cancer (BC) after treatment for Hodgkin's lymphoma (HL). We focused on the volume of breast tissue exposed to…”
Get full text

Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib by Follows, George A., Sims, Hannah, Bloxham, David M., Zenz, Thorsten, Hopper, Melanie A., Liu, Hongxiang, Bench, Anthony, Wright, Penny, van't Veer, Mars B., Scott, Mike A.

Get full text

Increased Risk of Stroke and Transient Ischemic Attack in 5-Year Survivors of Hodgkin Lymphoma by De Bruin, Marie L., Dorresteijn, Lucille D. A., van't Veer, Mars B., Krol, Augustinus D. G., van der Pal, Helena J., Kappelle, Arnoud C., Boogerd, Willem, Aleman, Berthe M. P., van Leeuwen, Flora E.

“…Background Information on clinically verified stroke and transient ischemic attack (TIA) following Hodgkin lymphoma is scarce. We quantified the long-term risk…”
Get full text

Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma by Travis, Lois B., Hill, Deirdre, Dores, Graça M., Gospodarowicz, Mary, van Leeuwen, Flora E., Holowaty, Eric, Glimelius, Bengt, Andersson, Michael, Pukkala, Eero, Lynch, Charles F., Pee, David, Smith, Susan A., Van't Veer, Mars B., Joensuu, Timo, Storm, Hans, Stovall, Marilyn, Boice, John D., Gilbert, Ethel, Gail, Mitchell H.

“…Background: Many women develop breast cancer after treatment for Hodgkin lymphoma (HL) at a young age. We estimated this future risk, taking into account age…”
Get full text

Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trial by Heutte, Natacha, PhD, Flechtner, Henning H, MD, Mounier, Nicolas, Prof, Mellink, Wilhelmina AM, MD, Meerwaldt, Jacobus H, MD, Eghbali, Houchingue, MD, van't Veer, Mars B, MD, Noordijk, Evert M, Prof, Kluin-Nelemans, Johanna C, Prof, Lampka, Elzbieta, MD, Thomas, José, MD, Lugtenburg, Pieternella J, MD, Viterbo, Luisa, MD, Carde, Patrice, MD, Hagenbeek, Anton, Prof, van der Maazen, Richard WM, MD, Smit, Wilma GJM, MD, Brice, Pauline, MD, van Marwijk Kooy, Marinus, MD, Baars, Johanna W, MD, Poortmans, Philip, MD, Tirelli, Umberto, MD, Leeksma, Onno C, MD, Tomšič, Radka, MD, Feugier, Pierre, MD, Salles, Gilles, Prof, Gabarre, Jean, MD, Kersten, Marie José, MD, Van Den Neste, Eric, MD, Creemers, Geert-Jan M, MD, Gaillard, Isabelle, MD, Meijnders, Paul, MD, Tertian, Gérard, MD, Reman, Oumédaly, MD, Muller, Hein P, MD, Troncy, Jacques, MD, Blanc, Michel, MD, Schroyens, Wilfried, MD, Voogt, Paul J, MD, Wijermans, Pierre, MD, Rieux, Chantal, BA, Fermé, Christophe, MD, Henry-Amar, Michel, Dr

“…Summary Background Little is known about the longitudinal course of health-related quality of life (HRQoL) in patients with Hodgkin's lymphoma during their…”
Get full text

Roles of Radiation Dose, Chemotherapy, and Hormonal Factors in Breast Cancer Following Hodgkin’s Disease by van Leeuwen, Flora E., Klokman, Willem J., Stovall, Marilyn, Dahler, Ellen C., van’t Veer, Mars B., Noordijk, Evert M., Crommelin, Mariad A., Aleman, Berthe M. P., Broeks, Annegien, Gospodarowicz, Mary, Travis, Lois B., Russell, Nicola S.

“…Background: Female survivors of Hodgkin’s disease (HD) have a strongly elevated risk of breast cancer, but factors responsible for the increased risk are not…”
Get full text

Second Cancers Among Long-Term Survivors of Hodgkin’s Disease Diagnosed in Childhood and Adolescence by METAYER, C, LYNCH, C. F, HOLOWATY, E. J, ANDERSSON, M, WIKLUND, T, GOSPODAROWICZ, M, TRAVIS, L. B, CLARKE, E. A, GLIMELIUS, B, STORM, H, PUKKALA, E, JOENSUU, T, VAN LEEUWEN, F. E, VAN'T VEER, M. B, CURTIS, R. E

“…To quantify the risk of second cancers among long-term survivors of Hodgkin's disease (HD) diagnosed before 21 years of age and to explore sex-, age-, and…”
Get full text

Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease by Fermé, Christophe, Eghbali, Houchingue, Meerwaldt, Jacobus H, Rieux, Chantal, Bosq, Jacques, Berger, Françoise, Girinsky, Théodore, Brice, Pauline, van't Veer, Mars B, Walewski, Jan A, Lederlin, Pierre, Tirelli, Umberto, Carde, Patrice, Van Den Neste, Eric, Gyan, Emmanuel, Monconduit, Mathieu, Diviné, Marine, Raemaekers, John M.M, Salles, Gilles, Noordijk, Evert M, Creemers, Geert-Jan, Gabarre, Jean, Hagenbeek, Anton, Reman, Oumédaly, Blanc, Michel, Thomas, José, Vié, Brigitte, Kluin-Nelemans, Johanna C, Viseu, Fernando, Baars, Joke W, Poortmans, Philip, Lugtenburg, Pieternella J, Carrie, Christian, Jaubert, Jérôme, Henry-Amar, Michel

“…This large trial showed that chemotherapy plus involved-field radiotherapy was superior to subtotal nodal radiotherapy alone in patients with localized stage…”
Get full text

Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease by Travis, Lois B, Hill, Deirdre A, Dores, Graça M, Gospodarowicz, Mary, van Leeuwen, Flora E, Holowaty, Eric, Glimelius, Bengt, Andersson, Michael, Wiklund, Tom, Lynch, Charles F, Van't Veer, Mars B, Glimelius, Ingrid, Storm, Hans, Pukkala, Eero, Stovall, Marilyn, Curtis, Rochelle, Boice, John D, Gilbert, Ethel

“…CONTEXT: Second cancer is the leading cause of death in long-term survivors of Hodgkin disease (HD), with exceptionally high risks of breast cancer among women…”
Get full text

A population-based case-cohort study of drug-associated agranulocytosis by van der Klauw, M M, Goudsmit, R, Halie, M R, van't Veer, M B, Herings, R M, Wilson, J H, Stricker, B H

“…Agranulocytosis is a life-threatening disorder, often caused by drugs. Incidences or risks of drug-induced agranulocytosis are not well known, since it is…”
Get more information

Survival after Hodgkin lymphoma by Favier, Olav, Heutte, Natacha, Stamatoullas‐Bastard, Aspasia, Carde, Patrice, van't Veer, Mars B., Aleman, Berthe M. P., Noordijk, Evert M., Thomas, José, Fermé, Christophe, Henry‐Amar, Michel

“…BACKGROUND: The objective of this study was to analyze cause‐specific excess mortality in adult patients with Hodgkin lymphoma (HL) with respect to treatment…”
Get full text

Treatment-related risk factors for premature menopause following Hodgkin lymphoma by De Bruin, Marie L., Huisbrink, Jeannine, Hauptmann, Michael, Kuenen, Marianne A., Ouwens, Gabey M., van’t Veer, Mars B., Aleman, Berthe M.P., van Leeuwen, Flora E.

“…We conducted a cohort-study among 518 female 5-year Hodgkin lymphoma (HL) survivors, aged 14 to 40 years (median: 25 years) at treatment (1965-1995)…”
Get full text

Optimal treatment of premature ovarian failure after treatment for Hodgkin's lymphoma is often withheld by Verschuuren, Sylvia I, Schaap, Jiska J, Veer, Mars B Van't, Stijnen, Theo, Burger, Curt W, Ansink, Anca C

“…The purpose of this study is to determine: 1. the effect of treatment for Hodgkin's lymphoma on ovarian function, and 2. the interventions to relieve…”
Get more information

The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia by Vojdeman, Fie Juhl, van't Veer, Mars B., Tjønnfjord, Geir E., Itälä-Remes, Maija, Kimby, Eva, Polliack, Aaron, Wu, Ka L., Doorduijn, Jeanette K., Alemayehu, Wendimagegn G., Wittebol, Shulamiet, Kozak, Tomas, Walewski, Jan, Abrahamse-Testroote, Martine C. J., van Oers, Marinus H. J., Geisler, Christian Hartmann

“…In the HOVON68 CLL trial, patients 65 to 75 years of age had no survival benefit from the addition of low-dose alemtuzumab to fludarabine and cyclophosphamide…”
Get full text

Screening for alloantibodies in the serum of patients receiving platelet transfusions: a comparison of the ELISA, lymphocytotoxicity, and the indirect immunofluorescence method by Levin, Mark-David, De Veld, Jos C., Van der Holt, Bronno, Van't Veer, Mars B.

“…BACKGROUND : For screening of alloimmunization in patients repeatedly receiving platelet transfusions, different tests are used, none of which is the standard…”
Get full text

The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia by van't Veer, MB, Brooijmans, AM, Langerak, AW, Verhaaf, B, Goudswaard, CS, Graveland, WJ, van Lom, K, Valk, PJ

“…Department of Hematology, Erasmus MC, Rotterdam, The Netherlands. m.vantveer@erasmusmc.nl BACKGROUND AND OBJECTIVES: The mutational status of the…”
Get full text

EDTA and temperature dependent neutrophil aggregation by Padayatty, Joseph, Lynn, Roderick, Scott, Mike A., Van't Veer, Mars B.

Get full text